ReviewJournal of translational medicine2026
Mitochondrial transfer: a Janus-faced force in health and disease.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Infection: Mitochondrial Reprogramming and Immunometabolic Adaptation inDiseases (Basel, Switzerland) · 2026Article
- Mitochondrial transfer: a new perspective on tumor-microenvironment crosstalk driving metastasis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mitochondrial transfer is increasingly recognized as a dynamic form of intercellular communication that reshapes how we understand tissue homeostasis, immune function, and disease progression. Rather than being a passive event, mitochondrial transfer involves the movement of organelles between cells through defined mechanisms, such as tunneling nanotubes, extracellular vesicles, or direct engulfment, altering the metabolic, epigenetic, and immunological profiles of recipient cells. In physiological and regenerative contexts, mitochondrial transfer contributes to cellular rescue, stem cell function, and organ recovery. However, in malignancies and infections, it can subvert immune surveillance, promote metabolic reprogramming, and reinforce pathological resilience. This dual capacity - simultaneously protective and pathogenic - positions mitochondrial transfer as a central yet ambivalent mechanism in health and disease. Beyond mechanistic insight, we explore its implications for emerging mitochondrial therapies, highlighting critical considerations in donor-recipient compatibility, organelle identity, and translational ethics. Mitochondrial transfer is increasingly recognized as a biologically significant process with both therapeutic potential and complex implications for our understanding of intercellular communication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.